Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 0 | $0 |
| Sells | 173 | $84,740,757 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 18 Mar 2025 12:27 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 17 Mar 2025 | Sale | 183 | 24.8237 | 4,543 | D |
| 06 Mar 2025 17:17 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 05 Mar 2025 | Sale | 5,569 | 25.1013 | 139,789 | D |
| 12 Feb 2025 13:59 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 11 Feb 2025 | Sale | 363 | 28.5388 | 10,360 | D |
| 30 Jan 2025 12:20 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 29 Jan 2025 | Sale | 695 | 29.5236 | 20,519 | D |
| 30 Jan 2025 12:18 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 29 Jan 2025 | Sale | 695 | 29.5236 | 20,519 | D |
| 30 Jan 2025 12:15 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 29 Jan 2025 | Sale | 546 | 29.5236 | 16,120 | D |
| 30 Jan 2025 12:13 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 29 Jan 2025 | Sale | 825 | 29.5236 | 24,357 | D |
| 30 Jan 2025 12:12 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 29 Jan 2025 | Sale | 364 | 29.5236 | 10,747 | D |
| 30 Jan 2025 12:10 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 29 Jan 2025 | Sale | 278 | 29.5236 | 8,208 | D |
| 30 Jan 2025 12:07 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 29 Jan 2025 | Sale | 826 | 29.5236 | 24,386 | D |
| 30 Jan 2025 12:03 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 29 Jan 2025 | Sale | 2,824 | 29.5236 | 83,375 | D |
| 30 Jan 2025 12:01 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 29 Jan 2025 | Sale | 365 | 29.5236 | 10,776 | D |
| 23 Jan 2025 15:41 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 22 Jan 2025 | Sale | 3,323 | 30.4255 | 101,104 | D |
| 23 Jan 2025 15:39 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 22 Jan 2025 | Sale | 3,323 | 30.4255 | 101,104 | D |
| 23 Jan 2025 15:37 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 22 Jan 2025 | Sale | 3,088 | 30.4255 | 93,954 | D |
| 23 Jan 2025 15:31 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 22 Jan 2025 | Sale | 3,948 | 30.4255 | 120,120 | D |
| 23 Jan 2025 15:29 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 22 Jan 2025 | Sale | 1,751 | 30.4255 | 53,275 | D |
| 23 Jan 2025 15:28 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 22 Jan 2025 | Sale | 13,551 | 30.4255 | 412,296 | D |
| 23 Jan 2025 15:26 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 22 Jan 2025 | Sale | 1,291 | 30.4255 | 39,279 | D |
| 23 Jan 2025 15:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 22 Jan 2025 | Sale | 3,948 | 30.4255 | 120,120 | D |
| 23 Jan 2025 15:23 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 22 Jan 2025 | Sale | 1,396 | 30.4255 | 42,474 | D |
| 23 Jan 2025 15:19 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 22 Jan 2025 | Sale | 1,096 | 30.4255 | 33,346 | D |
| 21 Jan 2025 16:14 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 17 Jan 2025 | Sale | 2,201 | 29.9582 | 65,938 | D |
| 21 Jan 2025 16:12 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 17 Jan 2025 | Sale | 2,201 | 29.9582 | 65,938 | D |
| 21 Jan 2025 16:11 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 17 Jan 2025 | Sale | 1,730 | 29.9582 | 51,828 | D |
| 21 Jan 2025 16:09 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 17 Jan 2025 | Sale | 2,145 | 29.9582 | 64,260 | D |
| 21 Jan 2025 16:07 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 17 Jan 2025 | Sale | 1,241 | 29.9582 | 37,178 | D |
| 21 Jan 2025 16:04 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 17 Jan 2025 | Sale | 6,007 | 29.9582 | 179,959 | D |
| 21 Jan 2025 16:02 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 17 Jan 2025 | Sale | 750 | 29.9582 | 22,469 | D |
| 21 Jan 2025 15:59 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 17 Jan 2025 | Sale | 1,235 | 29.9582 | 36,998 | D |
| 21 Jan 2025 15:56 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 17 Jan 2025 | Sale | 715 | 29.9582 | 21,420 | D |
| 21 Jan 2025 15:54 | APLS | Apellis Pharmaceuticals Inc | BAUMAL CAROLINE | Chief Medical Officer | 17 Jan 2025 | Sale | 1,853 | 29.9582 | 55,513 | D |
| 14 Jan 2025 16:30 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 13 Jan 2025 | Sale | 4,965 | 28.7021 | 142,506 | D |
| 14 Jan 2025 16:29 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 13 Jan 2025 | Sale | 2,685 | 28.7021 | 77,065 | D |
| 14 Jan 2025 16:25 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 13 Jan 2025 | Sale | 2,170 | 28.7021 | 62,284 | D |
| 14 Jan 2025 16:22 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Jan 2025 | Sale | 2,632 | 28.7021 | 75,544 | D |
| 14 Jan 2025 16:20 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 13 Jan 2025 | Sale | 1,599 | 28.7021 | 45,895 | D |
| 14 Jan 2025 16:18 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 13 Jan 2025 | Sale | 6,247 | 28.7021 | 179,302 | D |
| 14 Jan 2025 16:15 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 13 Jan 2025 | Sale | 264 | 28.7021 | 7,577 | D |
| 14 Jan 2025 16:14 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 13 Jan 2025 | Sale | 2,288 | 28.7021 | 65,670 | D |
| 14 Jan 2025 16:10 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 13 Jan 2025 | Sale | 1,599 | 28.7021 | 45,895 | D |
| 14 Jan 2025 16:09 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 13 Jan 2025 | Sale | 783 | 28.7021 | 22,474 | D |
| 08 Jan 2025 16:03 | APLS | Apellis Pharmaceuticals Inc | BAUMAL CAROLINE | Chief Medical Officer | 06 Jan 2025 | Sale | 2,816 | 33.812 | 95,215 | D |
| 27 Dec 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Dec 2024 | Sale | 63 | 33.09 | 2,085 | D |
| 13 Dec 2024 16:15 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 11 Dec 2024 | Sale | 5,000 | 34.235 | 171,175 | D |
| 17 Sep 2024 17:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 16 Sep 2024 | Sale | 7,524 | 36.79 | 276,808 | I |
| 17 Sep 2024 17:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 16 Sep 2024 | Sale | 29,476 | 36.09 | 1,063,789 | I |
| 17 Sep 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 16 Sep 2024 | Sale | 192 | 36.206 | 6,952 | D |
| 04 Sep 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 03 Sep 2024 | Sale | 550 | 39.491 | 21,720 | D |
| 21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 1,695 | 39.63 | 67,173 | I |
| 21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 35,305 | 39.22 | 1,384,662 | I |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 100 | 44.025 | 4,402 | D |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 22,472 | 42.849 | 962,903 | D |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 56,335 | 42.1504 | 2,374,543 | D |
| 09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 4,728 | 54.9152 | 259,639 | D |
| 09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 64,379 | 54.1165 | 3,483,966 | D |
| 02 Apr 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Apr 2024 | Sale | 4,000 | 58.66 | 234,640 | D |
| 20 Mar 2024 17:18 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 19 Mar 2024 | Sale | 18,681 | 57.179 | 1,068,161 | I |
| 19 Mar 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 18 Mar 2024 | Sale | 9,913 | 56.9 | 564,050 | D |
| 18 Mar 2024 16:19 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 15 Mar 2024 | Sale | 184 | 56.461 | 10,389 | D |
| 14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 3,452 | 58.1335 | 200,677 | D |
| 14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 7,768 | 57.307 | 445,161 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 100 | 63.35 | 6,335 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 26,257 | 62.6896 | 1,646,041 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 42,750 | 61.8754 | 2,645,173 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 413 | 65.68 | 27,126 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 116,512 | 64.9163 | 7,563,528 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 41,704 | 62.9631 | 2,625,813 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 62,503 | 64.2573 | 4,016,274 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 28,868 | 62.213 | 1,795,965 | D |
| 05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 2,000 | 63.95 | 127,900 | D |
| 05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 4,000 | 62.86 | 251,440 | D |
| 13 Feb 2024 17:06 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 12 Feb 2024 | Sale | 781 | 67.7669 | 52,926 | D |
| 13 Feb 2024 17:05 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
| 13 Feb 2024 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 12 Feb 2024 | Sale | 1,431 | 67.7669 | 96,974 | D |
| 13 Feb 2024 16:49 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 12 Feb 2024 | Sale | 3,962 | 67.7669 | 268,492 | D |
| 13 Feb 2024 16:43 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
| 13 Feb 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 12 Feb 2024 | Sale | 597 | 67.7669 | 40,457 | D |
| 31 Jan 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:36 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:34 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:31 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 29 Jan 2024 | Sale | 835 | 64.1382 | 53,555 | D |
| 31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 30 Jan 2024 | Sale | 883 | 65.53 | 57,863 | D |
| 31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
| 31 Jan 2024 16:26 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 29 Jan 2024 | Sale | 2,843 | 64.1382 | 182,345 | D |
| 31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 29 Jan 2024 | Sale | 279 | 64.1382 | 17,895 | D |
| 31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 30 Jan 2024 | Sale | 971 | 65.53 | 63,630 | D |
| 31 Jan 2024 16:21 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 29 Jan 2024 | Sale | 874 | 64.1382 | 56,057 | D |
| 31 Jan 2024 16:18 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
| 24 Jan 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 23 Jan 2024 | Sale | 4,286 | 63.69 | 272,975 | D |
| 24 Jan 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Jan 2024 | Sale | 7,378 | 63.69 | 469,905 | D |
| 23 Jan 2024 19:28 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 22 Jan 2024 | Sale | 13,431 | 64.996 | 872,961 | D |
| 23 Jan 2024 18:17 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 22 Jan 2024 | Sale | 4,184 | 64.996 | 271,943 | D |
| 23 Jan 2024 18:15 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 22 Jan 2024 | Sale | 3,413 | 64.996 | 221,831 | D |
| 23 Jan 2024 18:13 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 22 Jan 2024 | Sale | 3,551 | 64.996 | 230,801 | D |
| 23 Jan 2024 18:11 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 22 Jan 2024 | Sale | 2,593 | 64.996 | 168,535 | D |
| 23 Jan 2024 18:07 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 22 Jan 2024 | Sale | 1,738 | 64.996 | 112,963 | D |
| 23 Jan 2024 18:05 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 22 Jan 2024 | Sale | 1,607 | 64.996 | 104,449 | D |
| 23 Jan 2024 18:03 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 22 Jan 2024 | Sale | 3,913 | 64.996 | 254,329 | D |
| 23 Jan 2024 18:01 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 22 Jan 2024 | Sale | 1,384 | 64.996 | 89,954 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)